Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

2013238 citationsJournal Articlebronze Open Access

Authors

The observed safety/tolerability and clinical activity profile of sifalimumab support its continued clinical development for SLE.

Good health and well-being

Published in: Arthritis & Rheumatism

Volume 65, Issue 4, pp. 1011-1021

Field-Weighted Citation Impact: 33.27